Table 5.
Features of the currently licensed RVA vaccines RotarixTM and RotaTeqTM.
| RotarixTM | RotaTeqTM | |
|---|---|---|
| Manufacturer | GlaxoSmithKline | Merck |
| Dosage schedulea | Middle- & upper-income countries: 2 and 4 months of age. Low-income countries: 6 and 10 weeks of age. |
Middle- & upper-income countries: 2, 4 and 6 months of age. Low-income countries: 6, 10 and 14 weeks of age. |
| Route of administration | Oral | Oral |
| Formulation | Lypholized-reconstituted, and Liquid b | Liquid |
| Pooled efficacy c |
High-income countries: 94% against homotypic strains. 71% against partly heterotypic strains. 87% against fully heterotypic strains. Middle-income countries: 59% against homotypic strains. 72% against partly heterotypic strains. 47% against fully heterotypic strains. |
High-income countries: 83% against homotypic strains. 82% against single-antigen vaccine type strains. 82% against partly heterotypic strains. 75% against single-antigen non-vaccine type strains. Middle-income countries: 70% against single-antigen vaccine type strains. 37% against partly heterotypic strains. 87% against single-antigen non-vaccine type strains. |